This Market Spotlight report covers the Osteoarthritis market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts
- The author estimates that in 2016, there were 301.6 million prevalent cases of osteoarthritis (knee and hip) in adults aged 30 years and older worldwide, and forecasts that number to increase to 352.2 million by 2025.
- Global prevalence of osteoarthritis is estimated to be 8.2%. The majority of approved drugs in the osteoarthritis space target cyclooxygenases (COX-1, COX-2, and COX-3). Osteoarthritis therapies are commonly administered via the oral route, with a few products being available in topical and transdermal formulations.
- The majority of industry-sponsored drugs in active clinical development for osteoarthritis are in Phase II. Therapies in mid and late-stage development for osteoarthritis focus on a wide variety of targets. Among these therapies, Consensi is closest to market. The majority of the pipeline drugs in mid-to-late-stage development for osteoarthritis are administered via the intra-articular route.
- High-impact upcoming events for drugs in the osteoarthritis space include topline Phase III and Phase II trial results, and the FDA decisions on an NDA.
- There were 35 licensing and asset acquisition activities involving osteoarthritis drugs during 2013-17. The $454m license agreement between Novartis and XOMA, pursuant to which Novartis was granted a worldwide, exclusive, royalty-bearing license to XOMA’s gevokizumab program, was the largest deal during the 2013-2017 period.
- Cymbalta’s sales peaked in 2013 before declining due to generic erosion. While Cymbalta was once a blockbuster therapy, the majority of sales were for indications other than osteoarthritis.
- The clinical trials distribution across Phases I-IV indicates that the majority of drugs are in Phases I-II, with 56.9% of trials in Phases I-II and 43.2% in Phases III-IV.
- The US has a substantial lead in the number of osteoarthritis clinical trials globally, followed by the UK and Germany. Pfizer has the highest number of completed clinical trials for osteoarthritis, and also leads industry sponsors with the highest number of overall clinical trials for osteoarthritis, followed by Sanofi and Merck & Co.
1 KEY TAKEAWAYS
2 DISEASE BACKGROUND
- Non-pharmacological treatment
- Pharmacological treatment
5 MARKETED DRUGS
- Approvals by country
6 PIPELINE DRUGS
7 KEY UPCOMING EVENTS
8 KEY REGULATORY EVENTS
- First Approval For Kolon's Invossa But No Disease-Modifying Status
- Limited Japan Nod For Cytori’s Osteoarthritis Cell Therapy
9 LICENSING AND ASSET ACQUISITION DEALS
- Mitsubishi Seeks To Revoke Kolon Gene Therapy Deal But Damage Limited?
- Flexion Gets Osteoarthritis Gene Therapy From GeneQuine
10 PARENT PATENTS
11 REVENUE OPPORTUNITY
12 CLINICAL TRIAL LANDSCAPE
- Sponsors by status
- Sponsors by phase
- Recent events
- Prescription information
List of Figures
Figure 1: Trends in prevalent cases of osteoarthritis (knee or hip), 2016-25
Figure 2: Pipeline drugs for osteoarthritis in the US
Figure 3: Pipeline drugs for osteoarthritis, by company
Figure 4: Pipeline drugs for osteoarthritis, by drug type
Figure 5: Pipeline drugs for osteoarthritis, by classifications
Figure 6: Key upcoming events in osteoarthritis
Figure 7: Licensing and asset acquisition deals in disease name, 2012-17
Figure 8: Parent patents in osteoarthritis
Figure 9: Clinical trials in osteoarthritis
Figure 10: Top 10 drugs for clinical trials in osteoarthritis
Figure 11: Top 10 companies for clinical trials in osteoarthritis
Figure 12: Trial locations in osteoarthritis
Figure 13: Osteoarthritis trial status
Figure 14: Osteoarthritis trial sponsors, by phase
List of Tables
Table 1: Prevalent cases of osteoarthritis (knee or hip), 2016-25
Table 2: Marketed drugs for osteoarthritis
Table 3: Approvals by country for osteoarthritis
Table 4: Pipeline drugs for osteoarthritis in the US
Table 5: Historical global sales, by drug ($m), 2012-16
Table 6: Forecasted global sales, by drug ($m), 2017-22